COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
复制标题
DOI：
10.3390/biom11070993
复制
发表时间：
2021-07-06
期刊：
影响因子：
5.5
通讯作者：
Ranjan K
中科院分区：
文献类型：
--
作者：
Raman R;Patel KJ;Ranjan K
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）是2019冠状病毒病（COVID-19）大流行的病原体，一直是全球人类健康的主要关注话题。抑制COVID-19大流行的挑战因出现几种SARS-CoV-2变异株（即B.1.1.7（Alpha）、B.1.351（Beta）、P1（Gamma）和B.1.617.2（Delta））而进一步加剧，这些变异株显示出对疫苗和疗法的传播性和耐药性增加。重要的是，有令人信服的证据表明，免疫反应失调和合并症的个体对SARS-CoV-2感染的易感性增加。在此，我们提供了一个全面的观点，对潜在的医疗合并症患者的SARS-CoV-2感染的脆弱性。我们讨论正在进行的疫苗（mRNA，蛋白质为基础的，病毒载体为基础的，等等）。和治疗（单克隆抗体、小分子、血浆疗法等）旨在遏制COVID-19大流行的模式。我们还详细讨论了在地球仪上发现的不同SARS-CoV-2变异体（VOC）所带来的挑战及其对治疗和预防干预的影响。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, which has been a topic of major concern for global human health. The challenge to restrain the COVID-19 pandemic is further compounded by the emergence of several SARS-CoV-2 variants viz. B.1.1.7 (Alpha), B.1.351 (Beta), P1 (Gamma) and B.1.617.2 (Delta), which show increased transmissibility and resistance towards vaccines and therapies. Importantly, there is convincing evidence of increased susceptibility to SARS-CoV-2 infection among individuals with dysregulated immune response and comorbidities. Herein, we provide a comprehensive perspective regarding vulnerability of SARS-CoV-2 infection in patients with underlying medical comorbidities. We discuss ongoing vaccine (mRNA, protein-based, viral vector-based, etc.) and therapeutic (monoclonal antibodies, small molecules, plasma therapy, etc.) modalities designed to curb the COVID-19 pandemic. We also discuss in detail, the challenges posed by different SARS-CoV-2 variants of concern (VOC) identified across the globe and their effects on therapeutic and prophylactic interventions.